Lau C Y, Goldstein G
J Immunol. 1980 Apr;124(4):1861-5.
Cytotoxic lymphocyte precursor units (CLP-U) were enumerated in the spleens of C57BL/6 mice 3 days after i.p. injections of synthetic thymopoietin32-36 (TP5). One hundred to 1000 ng TP5/mouse potentiated splenic CLP-U, this effect being detectable only after suboptimal allogeneic sensitization (with 1.2 x 10(5) mitomycin-C treated DBA cells). This elevation of CLP-U persisted in the injected mice for at least 14 days. Control peptide did not affect CLP-U. In vitro incubation of 0.01 to 0.1 ng/ml of TP5 with normal C57BL/6 spleen cells also enhanced CLP-U after suboptimal allogeneic stimulation; high concentrations of TP5 caused suppression of CLP-U and this was detectable with optimal sensitization conditions. Thus TP5, in vitro and in vivo, appears to regulate immune responsiveness and this regulation varies with TP5 dosage and with the immune stimulus.
腹腔注射合成胸腺生成素32 - 36（TP5）3天后，对C57BL／6小鼠脾脏中细胞毒性淋巴细胞前体单位（CLP - U）进行计数。每只小鼠注射100至1000纳克TP5可增强脾脏CLP - U数量，这种效应只有在次优同种异体致敏（用1.2×10⁵经丝裂霉素 - C处理的DBA细胞）后才能检测到。CLP - U数量的增加在注射小鼠体内持续至少14天。对照肽不影响CLP - U数量。在次优同种异体刺激后，用0.01至0.1纳克/毫升的TP5与正常C57BL／6脾细胞进行体外孵育也可增强CLP - U数量；高浓度的TP5会导致CLP - U数量受到抑制，在最佳致敏条件下可检测到这种抑制作用。因此，TP5在体内和体外似乎都能调节免疫反应性，且这种调节随TP5剂量和免疫刺激的不同而变化。
